Parkinson’s Disease Debate
Full Debate: Read Full DebateDepartment: Foreign, Commonwealth & Development Office
Alex Easton
Main Page: Alex Easton (Independent - North Down)Department Debates - View all Alex Easton's debates with the Foreign, Commonwealth & Development Office
(1 day, 13 hours ago)
Westminster HallRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.
Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Paul Davies
Once again, I absolutely agree. I will certainly refer later to funding, which is a key issue. This is about resources and about making sure that that help is there as quickly as possible. Obviously, the longer it takes to provide that support, the more this disease hits people—the impact is far greater.
The Parky charter also addresses the personal independence payment system. As we know and as was said earlier, Parkinson’s is a fluctuating condition, and assessments often fail to capture its complexity. The Government are now working with Parkinson’s UK and individuals with lived experience to reform the PIP assessment, aiming to make it much more reflective of fluctuating conditions. The review is expected to report in autumn 2026, and the Minister has pledged that the voices of the Parkinson’s community will be central to the process. The Government have expressed a desire to return to routine face-to-face assessments, but have also indicated that for those with very severe conditions, full assessments may be waived if sufficient medical evidence is provided.
Alex Easton (North Down) (Ind)
In terms of treating those suffering from Parkinson’s, does the hon. Member agree that best practice should be shared across England, Scotland, Wales and Northern Ireland so that everybody gets the best treatment right across our United Kingdom?
Paul Davies
I could not agree more. I will speak later about the postcode lottery, although it is not just a postcode lottery; it is across the whole nation. The hon. Member is absolutely right: we should be doing everything we can to ensure consistency of support and adequate support across the nation.
Innovation also offers hope. Produodopa—I think I probably said that better today than the last time I was here—was approved for NHS use in 2024. Earlier today, I was at an event organised by Parkinson’s UK and I was talking to a specialist—a neurologist—who was talking about the impact of medication and how much difference that will make. It was fascinating, and that five minutes was of huge value in helping me to understand the impact.